ABSTRACT: Introduction: The neuropathy in patients with neurofibromatosis type 2 (NF2) is difficult to quantify and follow up. In this study we compared 3 methods that may help assess motor axon pathology in NF2 patients. Methods: Nerve conduction studies in median nerves were supplemented by deriving motor unit number estimates (MUNEs) from compound muscle action potential (CMAP) scans and by high-resolution ultrasound (US) peripheral nerve imaging.
Neurofibromatosis type 2 (NF2) is a hereditary tumor syndrome caused by loss of function mutations or deletion of the neurofibromatosis type 2 gene (NF2) located on chromosome 22q12. 1 This gene encodes merlin, a multifunctional cellular protein (reviewed recently 2 ). Symptoms of neuropathy are common in NF2, as there are paresthesias, sensory loss, weakness, and muscle atrophy. Neuropathic pain, however, occurs in only rare cases. [3] [4] [5] [6] [7] The aim of this study was to test novel methods that may help to quantify and follow-up NF2-associated neuropathy. For example, in the last few years, attempts to treat NF2 with pharmacological tools have led to the discovery that the antivascular antibody bevacizumab can stop the growth of tumors in many NF2 patients. [8] [9] [10] In addition, an anti-angiogenesis treatment has been described that can improve the neuropathy in a murine sciatic nerve model of NF2. 11 However, the effect of pharmacological treatment strategies on the NF2-associated neuropathy in patients has not yet been described. One reason for this may be the lack of methods suitable to quantify motor axon pathology in NF2.
A conventional electrophysiological examination of peripheral nerves includes, among other parameters, compound muscle action potential (CMAP) amplitude determination. This parameter, however, offers only a rough estimate of the number of functionally intact motor axons in peripheral nerves. Reinnervation by collateral sprouting may keep the amplitude constant in spite of a loss in the number of motor units and axons. 12, 13 In fact, apparently normal CMAPs have been recorded in amyotrophic lateral sclerosis (ALS), although the number of intact motor axons was reduced by 50%. 14 Several methods have been developed to estimate the number of intact motor units in a peripheral nerve (motor unit number estimation, MUNE). [15] [16] [17] It is now an accepted view that concurrent tracking of declines in MUNE and changes in single motor unit size over time are useful for research into the natural history of denervating disease, as well as the compensatory effects of collateral reinnervation. 17 Muscle action potential scans (CMAP scans) have also been found to be useful in several types of motor neuron diseases and neuropathies. 18, 19 In this study, we used the MScanFit program, recently developed by one of the authors (H.B.), to model a CMAP scan. 20 We demonstrate that this analysis software can reveal denervation and reinnervation in peripheral nerves and muscles in NF2 patients.
Peripheral nerve imaging carried out by highresolution ultrasound techniques can be performed with high spatial resolution, 21 and findings on the median nerve have been described. [22] [23] [24] It was shown that this method allows detection and quantification of schwannomas in peripheral nerves. 25 In this study, we combined CMAP scan MUNE with ultrasound imaging (US) to test whether these methods may help in quantification and follow-up of NF2-associated neuropathy.
METHODS
Patients. This study was based on measurements of 19 NF2 patients aged between 12 and 70 years (mean 6 SE: 34.5 6 2.9 years; 12 boys/men, 7 girls/ women). The diagnosis of NF2 in these patients was established on the basis of the modified National Institutes of Health criteria for definite NF2 26 and verified by genetic testing. Other concurrent causes for a neuropathy, such as diabetes mellitus and alcoholism, were excluded by means of medical history and laboratory testing. All procedures were approved by the local ethics committee of Hamburg University Hospital, and all patients gave written formal consent. Not all patients were examined by both electrophysiology and nerve ultrasound imaging on both arms. This was due to organizational reasons (studies in 2 clinical departments), a change in the study design from 1 arm to both arms, and insufficient CMAP recordings (see Results for details).
Electrophysiology. The CMAP scans were performed in the neurofibromatosis outpatient clinic of the Hamburg-Eppendorf University Hospital. QTRACW software (V C Institute of Neurology, London, distributed by Digitimer, Ltd., at www.digitimer.com) was available on a laptop computer with a Windows 7 operating system. The other components of the set-up were a DS5 isolated bipolar constant current stimulator (Digitimer, Ltd., Welwyn Garden City, UK), a data acquisition device (USB-6251-BNC; National Instruments, Munich, Germany), a 50-H Znoise eliminator (Hum Bug Science Products, Hofheim, Germany), and an amplifier with a bandwith of 3 HZ to 3 kHZ (Grass LP511 AC). Self-adhesive electrodes (Kendall ECG H92SG), with a round conducting area of 15 mm in diameter, were used for both stimulation and recording. The position of the electrodes was as with conventional use, stimulating the median nerve at the wrist and recording CMAPs from the motor point of the abductor pollicis brevis. Electrodes (Neuroline 71410-M/1; Ambu, Bad Nauheim, Germany) were used for grounding.
In addition, conventional electrodiagnostic testing of the median nerve (in particular, determination of nerve conduction velocities in the upper arm and the forearm) was performed in the neurophysiology laboratory of the Hamburg-Eppendorf University Hospital using an EMG measurement system (Neuropack X1; Nihon Kohden, Tokyo, Japan). In median motor nerve studies, the recording site was the abductor pollicis brevis muscle. Stimulation sites were chosen at the wrist, the antecubital fossa, and the axilla.
Muscle Action Potential Scans. The principles of CMAP scans or electrophysiological muscle scans have been described previously. 18, 19 The authors tested the importance of variables such as stimulation frequency, stimulus duration, and number of stimulus steps. 27 Analysis of CMAP scans has not yet been standardized. The method used in this study (MScanFit) has been described in detail in previous work. 20 MScanFit is available as part of the QTRACW threshold tracking software. It was chosen for its convenience and speed. In brief, the peak CMAP amplitude was recorded while stimuli were delivered at a frequency of 2 HZ. The stimulus current was decreased from just supramaximal in 0.2% steps to a current strength just below that necessary for the smallest measurable surface muscle action potential. The data plots were fitted by a model in which the CMAP was made up of a number of single motor unit potentials (SMUPs), each described by an amplitude, threshold, and relative spread (or coefficient of variation) of threshold. From this fitted model, the following derived parameters were used for the analyses: (1) number of SMUPs; (2) mean SMUP amplitude; and (3) largest SMUP amplitude.
Ultrasound Peripheral Nerve Imaging. Ultrasound examinations were performed using a Logiq E9 system (GE Healthcare) with an L8 18i linear hockey stick probe. To improve image quality, CrossXBeam (GE Healthcare) and compound imaging software were used. Median nerves were scanned in the transverse plane along their entire accessible length from axilla to wrist. Cervical roots and the brachial plexus were not scanned and are not included in this analysis. The cross-sectional area (CSA) of the median nerve was recorded at 4 predetermined sites: the carpal tunnel; at one-third of the forearm; the elbow; and at one-half of the upper arm. Fascicle diameters were measured in each median nerve at 3 different sites to generate normal diameter values (mean 6 SD: 0.6 6 0.13 mm).
All "nerve lesions" within the scanned segments of the median nerve were included in further analysis. Nerve lesions were defined as focal welldefined masses inside the epineurium with a middle-to-low homogeneous echogeneity, which allowed a clear differentiation of the lesion from unaffected fascicles. Only masses inside the epineurium with an enlargement of the fascicle diameter of >2-fold in comparison to the mean fascicle diameter were defined as focal "nerve lesions" or schwannoma-like fascicular enlargements. Because small nerve lesions did not result in an increase of the CSA of the affected nerve segment, the CSA was not used to define nerve lesions.
Statistics. GraphPad Prism (GraphPad, Inc., San Diego, California) and statistical analysis software in QTRACP were used for basic statistics and scatterplot regression lines. within a normal range of 5-8 mV (from base to peak amplitude). In contrast, the numbers of functionally intact motor axons differ clearly (from 35 to 120). It can also be seen that there is an inverse relationship between the number and mean amplitude of the SMUPs.
We also tested for a correlation between the estimated number of functionally intact motor fibers and other parameters (Fig. 2) . The graph in Figure 2A shows, not surprisingly, that larger CMAP amplitudes tended to be made up of greater numbers of SMUPs. On the other hand, it can be seen that some CMAPs of normal amplitude are seen in CMAP scans with a rather low number of functionally intact motor units.
No clear relationship was found between the number of motor units and the conduction velocity of the median nerve in the upper or lower arm (Fig. 2B) . The conduction velocity in all patients was within the normal range. On the other hand, a strong negative correlation was found between the number of functionally intact motor units and the amplitude of SMUPs (Fig.  2C) ; peripheral nerves with a reduced number of motor axons show larger amplitudes of both the mean and the largest amplitude SMUPs. This finding can be explained by reinnervation (see Discussion).
The MScan MUNE data from the NF2 patients were compared with recordings obtained from 18 control subjects (age 20-67 years; mean 6 SE: 38.6 6 3.5; 12 women, 6 men; 26 median nerves). A summary of the findings is presented in Figure 3 . In several of the NF2 patients, the number of functionally intact motor units is <70, despite a CMAP amplitude of >5 mV. It can be seen that an increase in the mean amplitude of SMUPs is the underlying factor.
Ultrasound Peripheral Nerve Imaging in Neurofibromatosis Type 2. The CSAs along the right and left median nerves of 14 NF2 patients were measured at the carpal tunnel, at one-third of the forearm, at the elbow, and at one-half of the upper arm.
A summary of the findings is presented in Table 1 . These data from NF2 patients can be compared with reference values for ultrasonography data of median nerves in control subjects. 22, 23 Based on these data, we did not find a general enlargement of the CSA.
On the other hand, a rather common observation in ultrasonographic images of NF2 patients was the presence of schwannoma-like fascicular enlargements. These are focal well-defined masses inside the perineurium with a middle to low homogeneous echogeneity, which allow clear differentiation from unaffected fascicles (Fig. 4) . All schwannoma-like fascicular enlargements ("nerve lesions") were in direct relationship to the median nerve. A centric location inside the median nerve was observed in 95% of cases, whereas 5% had an eccentric location. The contour exhibited welldefined margins in 72%, with poorly defined margins found in 28%. The shape was fusiform in 87%, and an oval shape was found in 13%. The internal echogeneity was homogeneous hypoechoic in 92%, and hyperechoic echogeneity was seen in 8%. An echogenic capsule, cystic changes, target signs, or microlobulations were not found in any of the "lesions." They were distant from each other and separated by nerve segments with normal fascicular structure. We did not detect any "nerve lesions" with diffuse and multilobular enlargement, which is characteristic for plexiform neurofibromas.
Schwannoma-like fascicular enlargements ("nerve lesions") were seen in 15 median nerves of the 26 median nerves studied in 14 patients. The number of these fascicular enlargements varied between 1 and >5 in affected nerves. Table 2 summarizes the number and size of the "nerve lesions." The diameter varied from >1.6 mm to 7 mm. For comparison, Schreiber et al. 22 reported a control fascicular diameter in the forearm median nerve of 0.60 6 0.21 mm (mean 6 SD).
Do Schwannoma-Like Fascicular Enlargements Correlate with CMAP Scan MUNE?. In 14 NF2 patients, both CMAP scan MUNE and high-resolution ultrasound images were obtained from 19 median nerves. We tested whether the number and size (diameter) of the schwannoma-like fascicular enlargements correlated with the loss of functionally intact motor axons in the median nerves of these NF2 patients. The data are presented in Figure 5 . There was a correlation between the number of lesions and the loss of functionally intact motor units. However, the regression line did not reach significance (P 5 0.065). This may have been due to some patients who had denervation of the thenar muscle, but had no "nerve lesions". Furthermore, the diameter of the largest schwannomalike fascicular enlargements did not clearly show a statistically significant correlation with the loss of functionally intact motor units. There may be more and larger "nerve lesions" in more proximal parts of the motor nerve fibers that were not visualized in this study.
DISCUSSION
In this study of NF2 patients, parameters of conventional neurography [maximal CMAP amplitude and nerve conduction velocity (CV)] were supplemented by CMAP scan MUNE and ultrasound imaging. The low amplitudes of the CMAP in some patients, together with normal CVs (Fig.  2) , are in accordance with the description of an "axonal" type of neuropathy in NF2 patients. 3, 5, 6 In comparison to conventional techniques, however, the CMAP scan analyses can provide more quantitative data about the number of functionally intact motor axons in peripheral nerves and can help to quantify the extent of denervation. For example, a rather low number of motor units could be seen, although the maximal amplitude of the CMAP was in the normal range ( Fig. 2A) .
In addition, denervation correlated with an increase in the amplitude of SMUPs. In fact, the mean amplitude of SMUPs was larger in nerves with low as compared to high numbers of functionally intact motor fibers (Fig. 2C) . This observation is similar to earlier reports on the characteristics of SMUPs in NF2, 3 and other partially denervated muscles, such as in ALS, Charcot-Marie-Tooth (CMT) neuropathy, diabetic neuropathy, and chronic demyelinating neuropathies. 12, 19, [28] [29] [30] [31] According to those studies, it is very likely that reinnervation of denervated muscle endplates by means of axonal collateral sprouting 12 was the underlying mechanism in NF2 patients as well. Taken together, the combination of a low number of functionally intact motor units and the increase in the mean amplitude of SMUPs (see Fig. 3 ) may help support the diagnosis of neuropathy in NF2 patients.
The high-resolution ultrasonography nerve images revealed the presence of "nerve lesions" (i.e., schwannoma-like fascicular enlargements) in many NF2 patients (Fig. 4) . These lesions may be small tumors (schwannomas) composed of proliferating Schwann cells, as described in histological studies of sural nerve biopsies in NF2 patients. [3] [4] [5] [6] 32 Visualization of nerve schwannomas has been described by ultrasound imaging, and a case report of a single NF2 patient has been published. 25, 33 Furthermore, multiple schwannomas along peripheral nerve trunks have been found in a recently developed murine model of NF2. 34 It is, however, important to note that US imaging in our study is restricted to the trunk of the median nerve between wrist and axilla. On the other hand, the follow-up of such known "nerve lesions" may be sufficient, for example, to monitor the effect of drug treatments on the size of peripheral nerve tumors in NF2.
The second parameter tested by ultrasound imaging in our study was the CSAs of several regions in the median nerves outside schwannomalike fascicular enlargements. The CSA data, however, did not differ from recently published reference values for ultrasonography of peripheral nerves (Table 1) . 22, 23 Therefore, it is unclear why nerve lesions/tumors in NF2 patients are restricted to only a few nerve regions.
By demonstrating specific ultrasound changes in NF2 patients, our study has shown that highresolution ultrasound can support the differential diagnosis of NF2-associated neuropathies from other hereditary or acquired neuropathies and entrapment syndromes. In contrast to hereditary demyelinating neuropathies, such as CMT1A and CMT1B, we did not see diffuse and extensive enlargement of the CSA or fascicular diameter of the median nerve. 22, 24, 35 In NF2 patients, CSA values and fascicular diameter did not differ from standard values in unaffected nerve segments. Nerve segments at entrapments sites, such as the carpal tunnel, were similarly not affected in NF2 patients, allowing differentiation from patients with hereditary neuropathy with liability to pressure palsies (HNPP) or entrapment syndromes. 24 Focal nerve enlargements were also described for acquired inflammatory demyelinating neuropathies, such as chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). In CIDP patients, either diffuse (37%-41%) or multifocal enlargement of nerves has been reported. 35, 36 Another ultrasound pattern seen in CIDP patients is large nerves with hypo-and hyperechoic fascicles. 37 As discussed earlier, we did not find similar diffuse or multifocal enlargements of the nerves/fascicles or changes in echogenicity in NF2 patients. In the NF2 cohort, increased CSA values were only detectable in short and clearly defined segments associated with schwannoma-like fascicular enlargements.
Only a few reports have described ultrasound images of tumors associated with large sensorimotor peripheral nerves in NF1. [38] [39] [40] These images showed low homogeneous echogeneity in single or multiple fascicles. Recently, possible criteria to distinguish neurofibroma from schwannoma in highresolution US nerve images have been discussed. 41 We emphasize that all patients in our study were diagnosed with NF2 according to current diagnostic criteria.
The pathogenesis of neuropathy in NF2 patients is unclear. One possible factor is the cumulative nerve compression caused by small tumors (schwannomas) or fascicular microlesions, as discussed in earlier studies. [3] [4] [5] [6] [7] 32 Our data provide some support for this view. On the other hand, we cannot exclude the possibility that other factors produce denervation in NF2 patients. Indeed, a clinical study showed that NF2 may affect peripheral nerve structures in a manner distinct from a compressive schwannoma. In relation to this, loss or diminution of merlin in peripheral nerve fibers that may cause the neuropathy in NF2 patients independent of the presence of Schwann cell tumors has been described. [43] [44] [45] The authors discussed an important role of merlin in neuronal cell types with regard to neuromorphogenesis, axon structure maintenance, and communication between axons and Schwann cells. Therefore, it is possible that NF2-related neuropathy has a multifactorial origin (as commented on by Morrison in the study by Plotkin et al. 46 . Also, there may be a combination of several factors. For example, small lesions due to proliferating Schwann cells may be atypically destructive for axons with abnormal expression of merlin. Such a combination of factors could explain why there is an asymmetric dysfunction of motor axons in some NF2 patients and why the functionally intact axons retain the ability for collateral sprouting.
In conclusion, our data show that CMAP scan MUNE and high-resolution US peripheral nerve imaging are useful complementary methods for assessing neuropathy in NF2 patients. These noninvasive methods may be helpful not only for the diagnosis but also to follow the time course of muscle denervation and reinnervation. In addition, repeated nerve imaging would enable observation of the development in the number and size of schwannoma-like fascicular enlargements. From a practical point of view, these methods would be feasible for routine use in specialized centers.
